Necitumumab resistance management

Necitumumab is a recombinant human anti-EGFR monoclonal antibody whose structure is similar to cetuximab. However, due to the lack of murine structure, allergic reactions are expected to be less common with cetuximab compared with cetuximab. In a phase 3 trial in first-line advanced non-squamous non-small cell lung cancer, nesituzumab was combined with pemetrexed and cisplatin.

If the tumor develops resistance to the drug Nexituzumab, resulting in poor treatment effect, the doctor should be informed promptly. The doctor may adjust the Xituzumab treatment plan based on the patient's drug resistance and disease progression. This may include changing drug doses, treatment intervals, or routes of administration to better address resistance. Depending on the patient's specific situation, switching to other treatment drugs, such as chemotherapy drugs, immunotherapy or targeted therapy drugs, or participating in relevant clinical trials, may be suitable alternative treatment options. However, everyone’s physique is different and their resistance to drugs is also different. If drug resistance occurs after using the drug, please inform your doctor in time and do not adjust the drug dosage yourself.

The generic drug of Nexituzumab has not yet been approved for marketing in China, and therefore it has not been included in medical insurance. The German version of the generic version of Nexituzumab available overseas800mg/50ml may cost more than RMB 10,000 per box (the price may fluctuate due to the exchange rate), which is relatively expensive. Currently, there is no generic version of Nexituzumab on the market. For more drug information and specific prices, please consult Yaode Medical Consultant.